Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Up 1,012.9% in January

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 2,090,000 shares, an increase of 1,012.9% from the December 31st total of 187,800 shares. Based on an average daily trading volume, of 6,360,000 shares, the short-interest ratio is currently 0.3 days. Currently, 3.7% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. StockNews.com started coverage on shares of Aptose Biosciences in a research report on Friday, January 24th. They issued a “hold” rating for the company. HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of Aptose Biosciences in a report on Friday, January 10th.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp raised its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Stock Down 10.0 %

Aptose Biosciences stock opened at $0.17 on Thursday. The business’s 50-day simple moving average is $0.21 and its 200 day simple moving average is $0.36. The stock has a market cap of $10.39 million, a price-to-earnings ratio of -0.06 and a beta of 0.87. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.20.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.